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A study was conducted to investigate the feasibility and acceptability of administering single-agent gemcitabine to patients with
advanced non-small-cell lung cancer (NSCLC) in their own homes. Gemcitabine is an active agent in NSCLC with a good toxicity
profile and lends itself to this type of investigation. A total of 24 patients were studied; as only one patient required gemcitabine to be
changed from home administration to hospital administration, domiciliary gemcitabine is feasible. A total of 249 injections of
gemcitabine were given, the mean number of courses being 3.5, range 1–6. The gemcitabine was given at 1000mgm
 2 on days 1, 8
and 15, the courses being repeated every 28 days. All patients received their first course in hospital and in total 147 were given at
home and only 14 in hospital on courses 2–6. Furthermore, both the patients and carers reported positively on the use of domiciliary
gemcitabine and preferred it over hospital administration. There was no evidence of increasing burden to community services during
the domiciliary chemotherapy. Further studies investigating this approach are warranted.
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Patients with advanced non-small-cell lung cancer (NSCLC)
treated with cisplatin chemotherapy have a statistically significant
increased survival compared with best supportive care alone
(NSCLC Collaborative Group, 1995; Cullen et al, 1999). The
survival benefit has been confirmed on a number of subsequent
randomised trials comparing the newer agents (vinorelbine,
paclitaxel, docetaxel) against best supportive care alone (Elvis,
1999; Ranson et al, 2000; Roszkowski et al, 2000). Furthermore, a
gemcitabine study demonstrated significant improvements in
relief of disease-related symptoms and quality of life (QoL)
assessed by an EORTC validated questionnaire, with a reduction in
hospitalisation and need for radiotherapy (Anderson et al, 2000).
Surveys have been conducted to address the concern about the
balance between what was perceived as being toxic therapy in a
palliative care setting vs the now known benefits of palliative
chemotherapy. When patients are asked about their views, they are
much more willing to accept chemotherapy than either healthy
individuals or health-care professionals (Slevin et al, 1990).
Furthermore, a study from the United States indicated that
patients valued relief of symptoms even though survival gain
may be short (Silvestri et al, 1998).
Gemcitabine has been evaluated in several trials in NSCLC and
has shown independent validated response rates of 18–26%, with
median survivals ranging from 6 to 12 months (Noble and Goa,
1997). Gemcitabine also improves disease-related symptoms in
more patients than those who obtained an objective tumour
response (Thatcher et al, 1995a,b, 1997). Gemcitabine has little
toxicity with minimal myelosuppression and alopecia (Aapro et al,
1998). The agent is relatively easy to give on an outpatient basis and
it was therefore considered suitable to evaluate in the domiciliary
setting. Perhaps surprisingly, no comparable bolus chemotherapy
study appears to have been reported. Domiciliary administration
could reduce patient waiting times in the hospital and increase the
time spent at home, which is known to be of importance to patients
and their families (Grande et al, 1998). However, the possible
disadvantages of home-based chemotherapy include missing the
support of other patients in a similar position, perhaps feeling less
secure at home and relatives finding the burden of caring for the
patient receiving home chemotherapy too great.
The prime objective of this study was to determine the feasibility
of administering gemcitabine in a domiciliary setting to patients
with locally advanced or metastatic NSCLC. The impact on the
patients’ QoL was also measured and an attempt was made to try
and determine the acceptability based on patient and carer views.
PATIENTS AND METHODS
A total of 24 patients with advanced, inoperable NSCLC were
entered into the study over 14 months. The protocol entry criteria
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lincluded no prior chemotherapy and eligibility required bulky
stage III (unsuitable for a resection or radiotherapy with curative
intent) or stage IV disease, histologically proven NSCLC with a
performance status of 0–2. Patients with active infection, brain
metastases, hypercalcaemia, a serum creatinine of more than
150mmoll
 1, bilirubin more than 1.5 times normal or transami-
nases more than three times the upper limit of normal were
excluded from the study. Patients were accepted if single-agent
gemcitabine was considered to be a reasonable alternative given
patient factors that were likely to compromise combination
chemotherapy, for example, cardiorespiratory comorbidity, etc.
Written informed consent was obtained and all patients were
analysed.
Study drug administration
Gemcitabine was administered as an intravenous infusion over
30min at a dose of 1000mgm
 2. Treatment was repeated weekly
for 3 weeks followed by a 1-week break. Cycles were repeated every
4 weeks for a maximum of six cycles. Patients’ disease-related
symptoms were assessed every 4 weeks. Toxicity and response
rates were assessed according to standard WHO criteria.
The first course of chemotherapy was administered in the
hospital. Prior to the second course of treatment, patients were
seen in the outpatient clinic, and blood taken for a full blood count
and biochemistry profile. If toxicity following the first course was
acceptable, the patient had the second and subsequent cycles of
chemotherapy at home. A specialist nurse collected the che-
motherapy from the hospital and administered it in the patients’
home. Patients were encouraged to telephone the in-patient ward
for advice and also had the telephone number of the specialist
chemotherapy nurse. A full blood count was taken at each visit,
days 8, 15 and 28 by the specialist nurse and used to dose the next
chemotherapy treatment. Toxicity and dose modifications were
defined by the same protocol whether in-patient or outpatient. If
grade 3/4 toxicity was present at the time of planned drug
administration, the dose was omitted. If gemcitabine was not given
for 6 weeks, then it was discontinued.
Primary end point
The primary end point was the feasibility of administering
gemcitabine in a domiciliary setting based on three components:
  Practicability – if the number of patients requesting reversion to
hospital care was less than 25%, then the approach was deemed
practical.
  Summaries of dose omission and patient discontinuations.
  Acceptability by assessing toxicity, QoL for patients and carers.
QoL assessments No more than 1 week before the first cycle
of chemotherapy, the patients’ QoL was assessed using the
EORTC-QLQ-C30 questionnaire with the LC13 module for lung
cancer. Patients also completed the Hospital Anxiety and
Depression scale (HADs). These measures were also completed
at the end of the second cycle, that is, the first cycle to be
administered at home.
Patients were asked to nominate a family member or friend who
was most involved in helping to support them at home. At the
same three points during the study, the nominated carer was asked
to complete three questionnaires: the Nottingham Health Profile
(Hunt et al, 1993), an extensively validated, concise measure of
subjective health status; the GHQ-28 (Goldberg and Hillier, 1979),
a widely used measure of psychiatric disturbance and the
Caregiver Strain Index (Robinson, 1983), a measure of the impact
of caring.
In addition to the QoL measure, both patients and carers were to
be approached for interview by an independent, experienced
research interviewer at the end of the second cycle of chemother-
apy. The interviews were to be semistructured and explored the
respondent’s experiences of receiving chemotherapy at home
rather than in the hospital. The responses to open questions were
recorded verbatim by the interviewer.
Secondary end points
Safety Clinical laboratory tests were carried out no more than 2
weeks before the patient enrolled into the study and during
the study. Changes in relevant laboratory and nonlaboratory
values were noted during the study, toxicity was rated using the
WHO scale at the end of each cycle and any adverse events
reported.
Tumour response No more than 3 weeks before enrolling into the
study, the disease status of each patient was assessed. Efficacy was
examined during the study at day 21 of each therapy cycle or in the
rest week to assess tumour response.
Resource utilisation A resource use analysis was performed on all
patients enrolled into the study. Data were collected for each
patient at the end of each cycle of chemotherapy. The data
collection period was from the date the patient entered the study
until 4 weeks after they received their final dose of gemcitabine.
For each patient, data were collected as follows:
Distances travelled
  By the patient (between their home and the hospital).
  By the domiciliary nurse between their base and the patient’s
home.
  Number of visits to the patient’s home to administer the
gemcitabine and the length of each of those visits.
Number and length of visits
  To the patients home by health-care professionals to deal with
adverse events or for any other reason.
  The number of admissions to hospital and the length of stay.
  The additional number of hours taken off work by the carer due
to the domiciliary administration of gemcitabine.
Statistical methods
Patient population, drug administration and feasibility The
baseline patient characteristics, details of chemotherapy adminis-
tration (number of doses, omissions, etc.) and feasibility were
summarised.
QoL/carer data Patient EORTC-QLQ-C30, LC13 and HAD scores
at baseline were compared to those after the second cycle of
chemotherapy. The differences between scores at baseline and
cycle 2 were not normally distributed: the Wilcoxon signed-rank
test was therefore used to test the statistical significance of these
differences.
The recommended weightings were used for only two of the
Nottingham Health Profile scales; the vast majority of scores on
the remaining scales were zero and McNemar’s test of paired
proportions was therefore used to detect differences in the
proportion of scores greater than zero between the two time
periods.
Responses to open questions on the patient and family
interviews were grouped into categories.
Safety and tumour response The incidence of toxicity grades was
summarised for the study population. The reasons for doses of
gemcitabine being omitted were also recorded. Physician-assessed
disease-related symptoms, tumour response and chemotherapy
toxicity were summarised.
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lResource utilisation data The distances travelled by the patient
and the domiciliary nurse were summarised for the study group.
The number and length of domiciliary nurse visits for gemcitabine
administration were reported for each cycle. In addition, the
average number of visits per patient by the other types of health-
care professionals (GP, District Nurse, Domiciliary Nurse, Other)
were summarised for each cycle. The number of patients who had
an in-patient stay during the study was noted and the average
length of stay was calculated. Although information was to be
collected on carer burden, unfortunately, there was only informa-
tion completed for five patient’s carers and the data were not
comprehensive enough to allow any summaries to be made.
RESULTS
Patient population
The patient characteristics are shown in Table 1. All patients were
Caucasian and the mean weight was 66kg (range 41–95). The
majority of patients had Zubrod performance status 1 (ambulatory
with symptoms) with 10 (42%) stage IIIB patients and 12 (50%)
stage IV patients. The patient with stage II tumour had a spiculated
3cm mass in the right upper lobe with a 6cm right hilar mass and
a subcarinal lymph node of uncertain significance with interstitial
lung disease where a definite diagnosis of lymphangitis could not
be excluded. This patient and the stage IIIA patient had been
reviewed by radiation oncologists and a surgeon for radical
treatment, but this was not deemed possible. Three patients had
received prior radiotherapy, to lymph node masses (2) and the
other to a lung mass, which was not in the site of the only
measurable disease.
Study drug administration
The median number of cycles was two, the mean 3.5 and the range
1–6. A total of 249 injections of gemcitabine were given. No
treatments were reduced. Six doses were delayed (three due to
holidays, one due to chest infection and two due to nausea and
vomiting).
Primary objective
Feasibility One patient was very anxious and fainted with the day
15 injection of the second cycle of gemcitabine, and all subsequent
gemcitabine was given in the hospital for this patient. It was
therefore considered that domiciliary administration was feasible
by the predetermined criterion as only one out of 24 (4%) patients
required hospital care for gemcitabine administration.
Dose omissions and patient discontinuations All patients received
their first cycle of chemotherapy in the hospital. Of the 72 planned
infusions of gemcitabine in the first cycle, four were omitted (ankle
oedema, chest infection, hypertension and flu-like symptoms).
According to protocol, all patients who tolerated gemcitabine in
the hospital should have their second course of chemotherapy at
home. Three patients did not have their domiciliary second cycle
as they had withdrawn from the study by this point due to lack of
efficacy of gemcitabine (2), and one due to flu-like side effects.
In the second cycle, five of the planned infusions were omitted,
four due to adverse events, mucositis, oedema, vomiting on two
occasions and one because the patient declined. Five doses of
gemcitabine were administered in the hospital during the second
cycle due to sore eyes, nausea, syncope and anxiety. The other
patient was seen in the hospital to assess pain, received the
gemcitabine in the hospital but had ongoing symptoms, so that
further gemcitabine was administered in the hospital, whereas the
fifth and sixth courses of gemcitabine were given at home. The
other four patients were assessed in the hospital and gemcitabine
was administered at the hospital visit, but all had their next
gemcitabine therapy at home.
Table 2 shows the proportion of planned gemcitabine treatments
given at home and in the hospital and the number of doses omitted
for each cycle. Five patients completed all six cycles. Six patients
received blood transfusions (a total of 14 units). In all, 20 patients
discontinued chemotherapy; five of these were due to adverse
events vomiting (course 3), hypertension (course 2), flu-like
symptoms (course 1) and dyspnoea (courses 2 and 4). One patient
died of a cerebral vascular accident and six patients with lung
cancer. The remaining seven were withdrawn due to perceived lack
of efficacy and one patient declined further treatment.
Of 147 domiciliary treatments only 14 were given in hospital. A
total of 20 planned doses were omitted, 11 because of toxicity
(oedema 2, infection 3, malaise 1, hypertension 1, vomiting 2,
mucositis 1, coryza 1) and nine because of the patient’s wish to
stop treatment at the time of day 15 infusion of gemcitabine during
the second, fifth and sixth cycles of therapy.
Acceptability – patient and carer QoL Of the 21 patients who
completed the second cycle of chemotherapy – the first being
administered at home – 16 provided QoL data. The median age of
those providing QoL data was 61.5 years compared to 62 years in
those who did not.
Scores on the role-functioning scale of the EORTC-QLQ-C30
declined significantly between the baseline and the end of the
second cycle of gemcitabine, but the other parameters did not
change significantly although there was a trend for worsening
appetite and constipation (Table 3).
The fatigue and nausea/vomiting scales showed statistically
significant increases, but the other items including financial
Table 1 Patient characteristics
Total 24
Males 15
Females 9
Median age (range) 62.6 years (45–79)
Zubrod performance status
0 3 (12%)
1 12 (50%)
2 9 (38%)
TNM stage
II 1 (4%)
IIIa 1 (4%)
IIIb 10 (42%)
IV 12 (50%)
Histology
Squamous 14 (58%)
Adenocarcinoma 6 (25%)
Undifferentiated 4 (17%)
Table 2 Gemcitabine administration
Number of infusions
Cycle
No. of
patients
No. of planned
infusions
Number
omitted Home Hospital
12 4 7 2 4— 6 8
2 21 63 5 53 (91%) 5 (9%)
3 15 45 5 35 (88%) 5 (12.5%)
4 12 36 2 31 (91%) 3 (9%)
5 6 18 2 16 (100%) 0
6 5 15 2 12 (92%) 1 (8%)
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ldifficulties were not significantly altered. Alopecia on the EORTC
Lung Cancer Module was significantly higher at the end of cycle 2
than at baseline, while cough was significantly improved (Table 4).
Changes in haemoptysis, pain in the chest and pain in other parts
approached statistical significance. The levels of anxiety and
depression as measured by the HADs scale did not increase
significantly between baseline and the end of cycle 2 (Table 5).
There were no statistically significant differences between the
baseline and the end of cycle 2 in the responses of informal carers
on the Nottingham Health Profile, GHQ-28 or Carer Strain Index
(Table 6).
Of the 13 patients who were interviewed at the end of cycle 2, 11
thought that having chemotherapy at home had advantages over
having it in the hospital, and all 13 thought it had no disadvantages
compared with having it in the hospital. All preferred having it at
home, and would recommend it to others in the same situation.
Two patients reported feeling more secure when having their
chemotherapy at home, one that they felt more secure in the
hospital and the remaining patients felt as secure at home as in the
hospital. Comments made by patients included that that they felt
more relaxed at home and found it less stressful (eight patients),
that home was better because there was no travelling involved (6),
that the hospital was worse because it took time to travel there and
Table 3 Comparison of quality-of-life (QoL) scores, as measured by
EORTC-QLQ-C30, before the first cycle of gemcitabine and after the
second cycle (the first to be administered at home) (N¼16)
Baseline:
mean
Cycle 2:
mean
Mean
difference
Wilcoxon
P
Functional scales
a
Physical functioning 60.9 52.5 8.44 0.65
Role functioning 57.3 38.5 18.8 0.01
Emotional functioning 65.4 61.8 3.68 0.22
Cognitive functioning 87.1 74.9 12.2 0.10
Social functioning 71.8 55.2 16.6 0.066
Global health status/QoL (QL2)
a 62.8 52.9 9.93 0.062
Symptom scales/items
b
Fatigue 32.3 49.3  16.9 0.02
Nausea and vomiting 14.6 32.2  17.7 0.02
Pain 17.6 23.9  6.31 0.61
Dyspnoea 49.7 49.7 0.00 0.81
Insomnia 28.9 24.8 4.12 0.75
Appetite loss 28.9 51.9  23.0 0.08
Constipation 16.6 37.2  20.7 0.053
Diarrhoea 0 6.6  6.60 0.08
Financial difficulties 22.7 16.5 6.25 0.16
aA high score for a functional scale or for the global QoL scale represents a high level
of functioning/QoL.
bA high score for a symptom scale/item represents a high level of
symptomatology/problems.
Table 4 Comparison of quality-of-life (QoL) scores, as measured by
EORTC Lung Cancer Module (LC13), before the first cycle of gemcitabine
and after the second cycle (the first to be administered at home) (N¼16)
N
Baseline:
mean
Cycle 2:
mean
Mean
difference
Wilcoxon
P
Dyspnoea 15 31.5 36.7  5.13 0.39
Coughing 16 43.3 26.8 16.5 0.021
Haemoptysis 16 8.25 0.00 8.3 0.10
Sore mouth 16 8.25 12.4  4.18 0.52
Dysphagia 16 8.25 10.31  2.06 0.74
Peripheral neuropathy 15 15.4 13.3 2.13 1.00
Alopecia 15 0.00 13.2  13.2 0.03
Pain in chest 16 16.5 8.3 8.25 0.10
Pain in arm or shoulder 15 11.00 13.2  2.2 0.70
Pain in other parts 15 13.2 24.3  11.1 0.096
A high score represents a high level of symptomatology/problems.
Table 5 Comparison of depression and anxiety scores, as measured by
the HADs, before the first cycle of gemcitabine and after the second cycle
(the first to be administered at home) (N¼16)
N
Baseline:
mean
Cycle 2:
mean
Mean
difference
Wilcoxon
P
Depression 16 4.87 7.25  1.37 0.055
Anxiety 16 7.19 8.56  2.37 0.14
A high score represents a high level of symptomatology/problems. HADs¼Hospital
Anxiety and Depression scale.
Table 6 Impact on informal carers: comparison of their health status, psychological morbidity and carer strain, before the first cycle of gemcitabine and
after the second cycle (the first to be administered at home) (N¼16)
McNemar’s test
N Baseline: mean Cycle 2: mean Mean difference 0 at cycle 2 (n) 1+ at cycle 2 (n) P
Nottingham Health Profile
Energy
a
0 at baseline 11 3 0.62
1/2/3 at baseline 11
Pain
0 at baseline 12 2 0.50
1/2/3/4/5 at baseline 02
Sleep 16 21.2 27.3  6.13 0.29
Emotional reactions 16 16.5 14.6 1.93 1.00
Social isolation
0 at baseline 9 4 0.38
1 at baseline 12
Physical mobility
0 at baseline 13 2 0.50
1 at baseline 01
GHQ 28
Total 17 4.76 3.53 1.23 0.21
Caregiver strain index 17 11.11 11.76  0.65 0.63
A high score represents a high level of symptomatology/problems.
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lto wait for treatment (6), that they preferred to be at home because
they could do what they wanted (including having a cup of tea,
going to bed immediately after treatment, having a cigarette) (4),
that it was better being in their own surroundings (3), that they got
better care at home (3) and that it was better because it did not
break up their routine (3).
Informal carers were also positive about home administration of
gemcitabine. All but one of those interviewed at the end of cycle 2
(17/18) thought that having it at home had advantages for the
family over having it in the hospital. Only two reported that it had
any disadvantages for the family: one felt very anxious about what
to do if there were problems, and the other thought that the side
effects of treatment might have been less in the hospital. All but
one preferred it when the patient had their chemotherapy at home,
and all but two would recommend it to other families in the same
situation (the two exceptions were unsure whether they would
recommend it). Comments made by informal carers included that
having treatment in the hospital involved a great deal of travelling
and this was avoided at home (12), that it took less time at home
and that there were no waiting times as in the hospital (11), that
home administration was better for the patient (9), that it was
more relaxing and less stressful to have treatment at home (7), they
preferred it because the patients were able to do what they wanted,
such as going to bed after treatment (5). Two carers mentioned
that it was more convenient for them if the patient had treatment
at home.
The patient’s reports gave a mean of 1.15h from the time the
nurse arrived to give chemotherapy at home until the nurse left. In
contrast, the patients’ visit to hospital for chemotherapy had taken
a mean of 7.04h from the time they left home until they got home
again; and the mean duration of the hospital visit was 5.73h.
Secondary objectives
Toxicity and tumour response Four patients had a partial
response (17%), 15 stable disease (63%) with progression in the
remainder. No grade IV toxicities were observed for any
parameter. However, grade III toxicities occurred for example
nausea, vomiting, neutropenia, haematuria and lethargy – see
Table 7 for the laboratory-based toxicity gradings and Table 8 for
nonlaboratory toxicities.
Resource utilisation
Distances travelled: The distances travelled by the patients from
their home to the hospital ranged from 2 to 83 miles. The average
distance was 29 miles (standard deviation¼28) and the median
was 15 miles. The distances travelled by the domiciliary nurse were
greater, ranging from 4 to 113 miles (mean¼51, standard
deviation¼29, median¼52). These distances did not include the
nurse travelling to the hospital to pick up the chemotherapy.
Domiciliary visits for gemcitabine administration: A total of 147
doses of gemcitabine were administered in the patients’ home and
domiciliary nurses made a total of 150 visits for this purpose. The
average length of time spent in the patients’ home was 80min and
this average was similar for each of cycles 2–6 individually.
Domiciliary visits not for gemcitabine administration: Table 9
shows the average number of domiciliary visits which each patient
had during each cycle. The average number of visits did not seem
to increase substantially throughout the duration of the study,
although the burden on the GP and district nurse was slightly
increased in cycle 2.
Hospitalisation: In all, 13 (54%) of the 24 study patients had an
in-patient stay during the study period, but no patient had more
than one in-patient stay. All the 13 hospitalisations were due to
adverse events (DVT, cerebral metastases, intermittent vomiting,
anaemia (2), cellulitis, dyspnoea (2), chest infection, vomiting,
hypercalcaemia and confusion. The average length of stay was 5.25
days.
Table 7 Worst WHO toxicity grades by patient for laboratory
parameters
Grade 0
(%)
Grade 1
(%)
Grade 2
(%)
Grade 3
(%)
Grade 4
(%)
Haemoglobin 10 (42) 10 (42) 3 (12.5) 1 (4) 0
WBC 14 (58) 5 (21) 3 (12.5) 2 (8) 0
Neutrophils 15 (63) 5 (21) 4 (16) 0 0
Platelets 21 (88) 1 (4) 1 (4) 1 (4) 0
AST/ALT 11 (46) 8 (33.5) 3 (12.5) 2 (8) 0
Alkaline phosphatase 17 (71) 4 (16) 2 (8) 1 (4) 0
Proteinuria 11 (46) 9 (38) 4 (16) 0 0
Table 8 Worst WHO toxicity grades by patient for nonlaboratory data
Grade 0
(%)
Grade 1
(%)
Grade 2
(%)
Grade 3
(%)
Grade 4
(%)
Haematuria 14 (58) 8 (33) 1 (4) 1 (4) 0
Haemorrhage 24 (100) 0 0 0 0
Oral 14 (58) 9 (37.5) 1 (4) 0 0
Nausea/vomiting 5 (21) 8 (33) 8 (33) 3 (12.5) 0
Diarrhoea 19 (79) 5 (21) 0 0 0
Pulmonary 23 (96) 0 1 (4) 0 0
Fever 20 (83) 4 (17) 0 0 0
Cutaneous 19 (79) 4 (17) 1 (4) 0 0
Alopecia 8 (33) 13 (54) 3 (12.5) 0 0
Infection 21 (88) 2 (8) 1 (4) 0 0
Lethargy 3 (12) 12 (50) 5 (21) 4 (17) 0
Peripheral 19 (79) 5 (21) 0 0 0
Constipation 14 (58) 9 (38) 1 (4) 0 0
Table 9 Visits not for administration of gemcitabine
No. of patients GP
Domiciliary nurse
District nurse
Other
Cycle In cycle With data AE Other Other AE Other Other
12 42 4 0 8 1 0 1 7 4
2 21 21 2 10 2 0 28 3
31 51 3 2 1 0 2 1 6 1
41 21 1 1 1 2 0 7 0
566 1 0 0 1 1 0
655 0 0 1 1 1 0
AE¼adverse events.
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lDISCUSSION
At the time of the study (1995), there were no data on the added
benefit of combining gemcitabine with platinum. The study did
allow better performance patients to enter; however, there were
comorbidities, for example, myocardial infarcts, pancreatitis,
chronic hearing difficulty, single kidney and patient preference
for a possible domicillary regimen. Furthermore, 58% of the
patients were receiving opiate-type medication on entry. As
reported in previous studies, gemcitabine administration was
associated with a reduction in some of the disease-related
symptoms (Thatcher et al, 1997). There was a statistically
significant reduction in patients’ cough between study entry and
the end of the second cycle of gemcitabine: reductions in
haemoptysis and pain in the chest approached statistical
significance. In contrast, alopecia, fatigue, nausea and vomiting
increased during the study, while there was a trend of appetite loss,
constipation and ‘pain in other places’ to increase. The mild flu-
like symptoms were not measured specifically by the QoL
measures used in this study, but could account for the increased
fatigue and of pain in places other than the chest. No specific
medication (other than steroids, routine analgesia) was given to
alleviate these symptoms at the time the study was performed.
However, the patient group over the study period received
considerable comedication – a mean of 24, median of 17 different
prescriptions, range 6–43.Cardiovascular agents were prescribed
to 14 patients, the same number of steroids, 17 opiates and 6
patients broncodilators.
The lower scores on the role functioning scale at the end of the
second cycle may be accounted for by increased levels of fatigue
(Aaronson et al, 1993). There was also some indication that both
cognitive and social functioning had declined, as well as global
QoL. Declines in functioning were in the ‘moderate’ range
according to Osoba’s work, relating changes in QoL scores to
patients’ perceptions of the magnitude of change; the reduction in
the global QoL score corresponded to a ‘little change’ (Osoba et al,
1998).
An alternative explanation for the reduction in some aspects of
QoL is that these were not due to gemcitabine per se, but its
administration at home. However, findings from the patient and
family interviews suggest that this is unlikely to be the explanation.
Patients and their carers were very positive about receiving
chemotherapy at home rather than in the hospital: only two out of
12 thought it had any disadvantages, and all but one would
recommend it to others in their situation. They reported feeling
more relaxed and finding it less stressful. The fact that it took less
time – an hour and a quarter compared to nearly 6h for the
hospital trip – was valued highly. Nevertheless, one in five, 13/16
of the patients included in the QoL analysis report declined to be
interviewed or was too ill. This may have introduced some bias
into the findings. Even if all three had found it a profoundly
negative experience, this would not have changed the overall
finding of the acceptability of the study – the majority of patients
were very positive about receiving gemcitabine at home and
preferred to it hospital care.
These findings are in agreement with previous studies that have
investigated the acceptability of a home nursing oncology service
in Australia (Lowenthal et al, 1996) and of a supportive home
treatment programme for cancer patients with haemotological
disorders (the majority of whom received blood and plasma
transfusions) (Stockelberg et al, 1997), and of chemotherapy at
home via continuous intravenous infusions (Sato et al, 1996).
None of these studies explored the impact on patients’ QoL using a
prospective study design or validated measures. The median
survival of 203 days (6.7 months) range 54–979 days was in line
with the randomised trial of single-agent gemcitabine plus best
supportive care vs best supportive care alone (Anderson et al,
2000).
Although patients may prefer domiciliary treatment, family
members and others providing informal care to these patients may
not. They may feel that it adds to the responsibilities that they
carry, and may prefer that the patient receive hospital treatment.
The importance of informal carers is increasingly recognised in
oncology and, in particular, in palliative care. The inability of
informal carers to continue to care due to exhaustion or to a lack
of confidence leads to hospital admissions. Caring can impose a
considerable load on informal carers, involving physical and
emotional labour, and often restricting their social and working
lives. Nevertheless, many report being glad to provide this care and
see it as a natural extension of bonds of kin and affection. The
Carers Act (1995) has stressed the importance of considering the
needs of carers in their own right, rather than taking for granted
that they will provide care when requested by the patient and/or by
health and social services.
The impact of caring on the lives of informal carers did not
increase between the baseline and the end of the second treatment
cycle, nor did the levels of psychiatric morbidity, or subjective
health status. Like the patients, the 17 informal carers who were
interviewed at the end of the second cycle were overwhelmingly
positive about the experience: they were pleased that the patients
had not had to travel, wait at hospital and they had been more
relaxed at home. The majority preferred home administration of
gemcitabine, and would recommend it – rather than hospital
treatment – to other families in the same situation.
From the available data, there does not appear to be any
increased burden on health-care professionals due to the
domiciliary administration of gemcitabine. Only three visits were
made to patients by the domiciliary nurse where the purpose was
to administer gemcitabine, but this was not possible. This has
implications for planning such a service as do the distances
travelled by the domiciliary nurse in order to administer the
treatment. It should be noted that one centre was located at some
distance from the domiciliary nurse base, and this has therefore
increased the distances travelled by the nurses.
The results of this feasibility study suggest that transferring the
administration of single-agent gemcitabine from the hospital to the
patients’ home (with effective nursing, medial support and clear
communication) is acceptable to both patients and carers.
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